Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT03502746
Phase: Phase II
Principal Investigator: Chiappori, Alberto
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
PRIMARY OBJECTIVES: Evaluate response rate [complete response (CR) + partial response (PR)] of nivolumab in combination with ramucirumab in subjects with previously-treated mesothelioma. Response assessment will be performed using modified RECIST 1.1 criteria as described by Byrne et al. SECONDARY OBJECTIVE(S): Characterize adverse effects (AE) of nivolumab in combination with ramucirumab in subjects with previously-treated mesothelioma. Measure progression-free survival (PFS) rate at 24 weeks with the combination of the anti-Programmed Death 1 (PD-1) agent, nivolumab and the anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, ramucirumab in subjects with previously-treated mesothelioma. Measure overall survival (OS) at 2 years after treatment with nivolumab in combination with ramucirumab in subjects with previously-treated mesothelioma. CORRELATIVES OBJECTIVES: Correlate programmed death-ligand 1 (PD-L1) expression in tumor tissue (from biopsy before treatment) with best clinical response (modified RECIST 1.1 criteria) in subjects with previously-treated mesothelioma. Correlate change in PD-L1 expression in tumor tissue from before therapy (assessed within 14 days before treatment) to after 4 cycles (8 weeks) of therapy with best clinical response (modified RECIST 1.1 criteria) at the end of Cycle 4 (Week 8) in subjects with previously-treated mesothelioma. Correlate cytokine genes expressions and change in tumor tissue (such as IL-1, IL-2, IL-6, GM-CSF, IL-10, IL-12, T-bet, IRF1, IFNã, CXCL1, CXCL9, CXCL10, CCL2 and 5) from before therapy (assessed within 14 days before treatment) to after 4 cycles (8 weeks) of therapy with best clinical response (modified RECIST 1.1 criteria) at the end of Cycle 4 (Week 8) in subjects with previously-treated mesothelioma. Correlate change in soluble PD-L1 level in plasma during therapy (assessed pre-dose Cycles 1 and 5 [Days 1 and 57 of treatment period, respectively]), with best clinical response (modified RECIST 1.1 criteria) at the end of Cycle 4 (Week 8) in subjects with previously-treated mesothelioma. Correlate change in number of CD8+, Granzyme B+ T cells in tumor tissue from before therapy (assessed within 14 days before treatment) to after 4 cycles (8 weeks) of therapy with best clinical response (modified RECIST 1.1 criteria) at the end of Cycle 4 (Week 8) in subjects with previously-treated mesothelioma.
Immunotherapy; Therapy (NOS)
BMS-936558 (Nivolumab); IMC-1121B (Ramucirumab); Nivolumab (Opdivo); Ramucirumab ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday